Concepedia

Author

Gabriella Fontanini

University of PisaORCID

Also Known As

Anna S. Petronio, Camilla Comin, F Zanelli, Fontanini, G FONTANINI, G Fontanini, G. Ali, G. Fontanini, G., Fontanini, GABRIELLA FONTANINI

503

Publications

19.8K

Citations

70

H-Index

130

Concepts

All Affiliations

University of PisaAzienda Ospedaliera Universitaria PisanaUniversity of Naples Federico IIIstituti di Ricovero e Cura a Carattere ScientificoIstituto Oncologico Veneto
GF

About

Gabriella Fontanini is an author at University of Pisa specializing in medicine, pathology, and oncology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

47

117

10.1K

2

Health Sciences

9

9

805

3

Engineering

3

3

291

4

Allergy

1

1

10

5

Biomedical Engineering

1

1

56

Gabriella Fontanini

×

238

Publications

18.3K

Citations

67

H-Index

YearCitations

FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study

Chiara Cremolini, Fotios Loupakis, Carlotta Antoniotti,

The Lancet Oncology

2015

1.1K

Relation of neovascularisation to metastasis of non-small-cell lung cancer

Paolo Macchiarini, Gabriella Fontanini, F Squartini,

The Lancet

1992

771

Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor.

Fortunato Ciardiello, Rosa Caputo, Roberto Bianco,

PubMed

2001

644

PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients

Armida D’Incecco, Mariacarla Andreozzi, Vienna Ludovini,

British Journal of Cancer

2014

601

ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases.

Francesca Carlomagno, Donata Vitagliano, Teresa Guida,

PubMed

2002

570

KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer

Fotios Loupakis, Annamaria Ruzzo, Chiara Cremolini,

British Journal of Cancer

2009

557

Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells.

Fortunato Ciardiello, Roberto Bianco, V. Damiano,

PubMed

2000

380

Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase.

Fortunato Ciardiello, Rosa Caputo, Vincenzo Damiano,

PubMed

2003

329

Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial

Chiara Cremolini, Carlotta Antoniotti, Daniele Rossini,

The Lancet Oncology

2020

309

Vascular endothelial growth factor is associated with neovascularization and influences progression of non-small cell lung carcinoma.

Gabriella Fontanini, S. Vignati, Laura Boldrini,

PubMed

1997

307

Page 1